Coronary Trials
- OASIS 9
A multicenter, international SYNERGY Stent registry that is embedded within a randomized, blinded, double-dummy, 2×2 factorial design trial of colchicine versus placebo and spironolactone versus placebo in patients with ST-elevation myocardial infarction who have undergone primary percutaneous coronary intervention (PCI).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03048825
- Victorion 2 Prevent
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Peripheral Trials
- CREST II
Carotid revascularization and medical management for asymptomatic carotid stenosis trial
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02089217
- TARGET BP
A randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation – no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT02910414
- Elegance
The ELEGANCE Registry’s objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT04674969?term=04674969&draw=2&rank=1
Structural Heart Trials
- AMPLATZER™ PFO Occluder Post-Approval Study
AMPLATZER™ PFO Occluder Post Approval Clinical Study is a single arm, multi-center study to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder, in a post approval setting, in patients with a PFO who have had a cryptogenic stroke confirmed by a study neurologist.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03309332
- ACURATE IDE
A prospective, multicenter trial designed to evaluate the safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for TAVR in subjects who have sever native aortic stenosis and are indicated for TAVR.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Website pending…
- SUMMIT
Prospective, controlled, multicenter clinical investigation of the Tendyne Mitral Valve System for the treatment of eligible subjects with symptomatic, severe, mitral regurgitation.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Website pending…
- CHAMPION AF
This study is a prospective, randomized, multi-center global investigation. Subjects will be randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device (“Device Group”) or a commercially available non-vitamin K oral anticoagulant (“Control Group”).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT04394546?term=champion+af&cntry=US&draw=2&rank=1
- Empower
The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the CARILLON Mitral Contour System in treating heart failure with at least mild functional regurgitation.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
EP Trials
- SOLVE CRT
A prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-LV System for Cardiac Re-synchronization Therapy. The WiSE-LV System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/study/NCT02922036
- INTERRUPT AF
A prospective, non-randomized, multicenter (global), post approval clinical study (PAS) to evaluate open irrigated ablation catheters with high resolution mapping to treat paroxysmal atrial fibrillation.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT03729830
- ARCADIA
Description coming soon…
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- iCLAS
Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- HEAL
The objective of this study is to gather information on participants returning at time of CIED change-out or revision who underwent a device implantation with either a CanGaroo® envelope, Tyrx™ envelope, or no envelope.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT04645173?cond=cangaroo&draw=2&rank=1
- Newton AF
Study to establish the safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Avier
A prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
- Huya Bio
This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
Heart Failure Trials
- Rebalance HF
The objective of this clinical evaluation is to assess the safety and initial effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com
https://clinicaltrials.gov/ct2/show/NCT04592445?cond=rebalance+hf&draw=2&rank=1
Registry
- Care HF
Cardiovascular and renal treatment in heart failure patients with Hyperkalemia or at high risk of hyperkalemia
If you would like additional information regarding this trial please visit the website below or contact researchopportunities@prairieresearch.com